Lyell Immunopharma Inc. (LYEL)
NASDAQ: LYEL
· Real-Time Price · USD
10.59
-0.17 (-1.58%)
At close: Aug 15, 2025, 3:47 PM
-1.58% (1D)
| Bid | 7.84 |
| Market Cap | 203.45M |
| Revenue (ttm) | 65K |
| Net Income (ttm) | -334.52M |
| EPS (ttm) | -24.26 |
| PE Ratio (ttm) | -0.44 |
| Forward PE | -0.76 |
| Analyst | Hold |
| Ask | 13.69 |
| Volume | 27,152 |
| Avg. Volume (20D) | 143,863 |
| Open | 11.04 |
| Previous Close | 10.76 |
| Day's Range | 10.59 - 11.27 |
| 52-Week Range | 7.65 - 32.40 |
| Beta | -0.20 |
About LYEL
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol LYEL
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for LYEL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
+19.31%
Lyell Immunopharma shares are trading higher after...
Unlock content with
Pro Subscription
9 months ago
+19.35%
Lyell Immunopharma shares are trading higher. The stock may be moving on continued strength after the company announced yesterday it will present clinical data from its Phase 1-2 trial of IMPT-314 CAR T-cell therapy for B-cell lymphoma at ASH 2024.
